Gefitinib, an oral inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, was initially employed in the late 1990s as a form of molecularly targeted therapy for NSCLC.107. Here, EGFR is linked to non-small cell lung carcinoma.